financetom
Business
financetom
/
Business
/
Vox Royalty Down 2% After Hours as Its Q4 Loss Doubles, But Increases Its Dividend On 2025 Outlook
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Vox Royalty Down 2% After Hours as Its Q4 Loss Doubles, But Increases Its Dividend On 2025 Outlook
Feb 20, 2025 2:27 PM

05:10 PM EST, 02/20/2025 (MT Newswires) -- Vox Royalty ( VOXR ) was last seen down 2% in after-hours Nasdaq trading after saying Thursday its loss for the fourth quarter doubled even as it hiked its quarterly dividend to reflect its 2025 outlook.

Vox reported a loss of US$966,494 or US$0.02 per share, in the quarter, compared to a loss of US$417,962 or US$0.01, a year earlier.

Fourth-quarter revenue edged down to US$2.9 million from US$3 million.

In its outlook, Vox said the performance of its portfolio during the year was generally in line with management expectations. In March, 2024, Vox estimated its 2024 royalty revenue would be in the range of US$11 million to US$13 million. For the year, Vox's royalty revenue totaled $11.05 million.

For 2025, Vox estimates royalty revenue to total US$12 million to US$14 million.

The company's board raised its quarterly dividend to $0.0125 per share from US$0.012, to be paid on April 14, to shareholders of record on March 31. It said this marks the third consecutive annual increase for Vox shareholders.

Kyle Floyd, Chief Executive Officer, said: "We are pleased to announce record annual cashflows from operations, achievement of annual revenue guidance for the fourth consecutive year and finishing 2024 with three new producing gold royalties in Western Australia. We are also encouraged to deliver annual G&A expenditure reduction of 9%, demonstrating management's ongoing focus on operating efficiency."

Vox Royalty ( VOXR ) was last seen down $0.05 to US$2.50 after hours. They closed up $0.11, or 3.1%, tot $3.66 on the Toronto Stock Exchange.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Union Pacific mostly restores operations in Texas following storm Beryl
Union Pacific mostly restores operations in Texas following storm Beryl
Jul 9, 2024
July 9 (Reuters) - Union Pacific ( UNP ) said on Tuesday it has mostly resumed operations impacted due to Hurricane Beryl in Texas but expects some disruptions till commercial power and road accessibility are fully restored. All impacted track segments, with the exception of the Galveston area have been quickly restored to service, the railroad operator said. The storm...
--Foreign Carmakers Outproduce Detroit's Big 3 in US for 1st Time
--Foreign Carmakers Outproduce Detroit's Big 3 in US for 1st Time
Jul 9, 2024
01:47 PM EDT, 07/09/2024 (MT Newswires) -- Price: 46.64, Change: +0.09, Percent Change: +0.18 ...
Cosmos Health to Manufacture 500,000 Units of CBD Products For Australian Firm
Cosmos Health to Manufacture 500,000 Units of CBD Products For Australian Firm
Jul 9, 2024
02:56 PM EDT, 07/09/2024 (MT Newswires) -- Cosmos Health ( COSM ) said Tuesday its Cana Laboratories subsidiary has secured a contract to produce 500,000 units of CBD products for Humacology, a privately held wellness company in Australia. Financial terms were not disclosed. Shares of Cosmos Health ( COSM ) were up about 1.6% in recent trading, easing from a...
Eli Lilly's $3.2B Morphic Deal Is 'Crucial,' Has 'Strategic Merit' Despite Investor Attention On Obesity: Analyst
Eli Lilly's $3.2B Morphic Deal Is 'Crucial,' Has 'Strategic Merit' Despite Investor Attention On Obesity: Analyst
Jul 9, 2024
Eli Lilly And Co ( LLY ) agreed to acquire Morphic Holding Inc ( MORF )  for $57 per share in cash, an aggregate of approximately $3.2 billion. Lead asset MORF-057 is a small-molecule inhibitor that is currently in Phase 2b trial for ulcerative colitis, with a readout expected in the first half of 2025. It recently initiated a Phase 2 study in Crohn’s disease. Also...
Copyright 2023-2026 - www.financetom.com All Rights Reserved